Akston Biosciences Corporation

Smartcells, Inc.

National Institutes of Health, a Component of the US Dept. of Health & Human Services

National Institutes of Health (nih)

The United States of America As Represented by Nih Division of Extramural Inventions and Technology Resources (deitr)

Askton Bioscences Corporation

Akston Bioscience Corporation

Dechra Limited

Vakston, Inc.

Thomas M Lancaster

Todd C Zion

Thillainayagam Sathiyaseelan

Kexin Huang

Sylaja Murikipudi

Wenyi Cai

Ryan Faucette

Matthew Pecukonis

Zhiyu Chen

Rassol Laleau

Matthew Nalewanski

Robert Butters

Naomi Choodnovskiy

The present disclosure provides recombinantly manufactured fusion proteins comprising a Programmed Death-Ligand 1 (PD-L1) protein fragment or an analog thereof linked to a canine Fc fragment. Embodiments include the administration of the fusion proteins to patients as a treatment for cancers, tumors or other diseases associated with expression of the PD-L1 protein in dogs. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

PD-L1 analog fusion proteins for antigen specific immunotherapy and methods of use

The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 Receptor Binding Domain (SARS-CoV-2-RBD) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID-19 as a booster vaccination, to antibody naïve patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

Antigen specific immunotherapy for COVID-19 fusion proteins and methods of use

The present disclosure relates to compositions of insulin-Fc fusion proteins and their use to treat feline diabetes.

Ultra-long acting insulin-Fc fusion protein and methods of use

The present disclosure relates to compositions of insulin-Fc fusion proteins and their use to treat diabetes.

Ultra-long acting insulin-Fc fusion protein

A sliding mattress accessory is used with an existing mattress support system coupled to an RV slide-out. The accessory includes a secondary deck with a fixed head section, a long deck section and a hinge. The system also includes two long sliding rails longitudinally aligned and mounted to the secondary deck's bottom surface and the primary deck's top surface used with the existing mattress support system. The system includes at least one support mounted on the top surface of the primary deck that supports the fixed head section. The two sliding rails and the fixed support are the same height so the entire secondary deck is elevated approximately 3 inches above the primary deck. A lock mechanism prevents the secondary deck from moving longitudinally over the primary deck. When assembled, the secondary platform is aligned and registered over the primary deck, and a mattress is placed over the secondary deck.

RV sliding mattress deck accessory

The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating canine diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of canine origin. Based on the results obtained, creating a treatment that is amenable to low cost manufacturing, exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, does not induce anti-drug antibodies, and substantially retains is potency over multiple administrations, requires a non-obvious combination of insulin polypeptide, peptide linkers, and species-specific Fc fragment, in addition to selective mutations on one or more of these components. Exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided, in addition to methods of use and preparation.

Ultra-long acting insulin-Fc fusion proteins and methods of use

The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating canine and feline diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of canine or feline origin. Based on the results obtained, creating a treatment that is amenable to low cost manufacturing, exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, does not induce anti-drug antibodies, and substantially retains is potency over multiple administrations, requires a non-obvious combination of insulin polypeptide, peptide linkers, and species-specific Fc fragment, in addition to selective mutations on one or more of these components. Exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided, in addition to methods of use and preparation.

The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 Receptor Binding Domain (SARS-CoV-2-RBD) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID-19 as a booster vaccination, to antibody na&#xef;ve patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

The present disclosure relates to compositions of fusion proteins, e.g., insulin-Fc fusion proteins, and their use to treat cancer cells and cancer tumors.

Insulin-Fc fusion proteins and methods of use to treat cancer

The present disclosure provides cells engineered to express recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of human origin. Exemplary ultra-long acting insulin-Fc fusion proteins, cells engineered to express the fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided, in addition to methods of use and preparation.

Cells engineered to express ultra-long acting insulin-Fc fusion proteins

The present disclosure relates generally to compositions of insulin-Fc (e.g., proinsulin-Fc) fusion proteins and their use to treat autoimmune disease, e.g., autoimmune diabetes, e.g., Type 1 diabetes.

Insulin-Fc fusions and methods of use

The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of human origin. Exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided.

Growing community of inventors

Stoneham, MA, United States of America

Thomas M Lancaster